Suppr超能文献

拉丁美洲家族性高胆固醇血症全景:一项系统综述。

The panorama of familial hypercholesterolemia in Latin America: a systematic review.

作者信息

Mehta Roopa, Zubirán Rafael, Martagón Alexandro J, Vazquez-Cárdenas Alejandra, Segura-Kato Yayoi, Tusié-Luna María Teresa, Aguilar-Salinas Carlos A

机构信息

Departamento de Endocrinologia y Metabolismo, Instituto Nacional de Ciencias Médicas y Nutrición "Salvador Zubirán", Mexico City, Mexico.

Escuela Nacional de Medicina, Tecnológico de Monterrey, Monterrey, Mexico.

出版信息

J Lipid Res. 2016 Dec;57(12):2115-2129. doi: 10.1194/jlr.R072231. Epub 2016 Oct 24.

Abstract

The burden caused by familial hypercholesterolemia (FH) varies among countries and ethnic groups. The prevalence and characteristics of FH in Latin American (LA) countries is largely unknown. We present a systematic review (following the PRISMA statement) of FH in LA countries. The epidemiology, genetics, screening, management, and unique challenges encountered in these countries are discussed. Published reports discussing FH in Hispanic or LA groups was considered for analysis. Thirty studies were included representing 10 countries. The bulk of the data was generated in Brazil and Mexico. Few countries have registries and there was little commonality in FH mutations between LA countries. LDL receptor mutations predominate; APOB and PCSK9 mutations are rare. No mutation was found in an FH gene in nearly 50% of cases. In addition, some country-specific mutations have been reported. Scant information exists regarding models of care, cascade screening, cost, treatment effectiveness, morbidity, and mortality. In conclusion, FH is largely underdiagnosed and undertreated in the LA region. The genetic admixture with indigenous populations, producing mestizo's groups, may influence the mutational findings in Latin America. Potential opportunities to close gaps in knowledge and health care are identified.

摘要

家族性高胆固醇血症(FH)所造成的负担在不同国家和种族群体中有所不同。拉丁美洲(LA)国家中FH的患病率和特征在很大程度上尚不明确。我们对LA国家的FH进行了一项系统综述(遵循PRISMA声明)。讨论了这些国家中FH的流行病学、遗传学、筛查、管理以及所面临的独特挑战。纳入分析的是讨论西班牙裔或LA群体中FH的已发表报告。共纳入了代表10个国家的30项研究。大部分数据来自巴西和墨西哥。很少有国家建立了登记系统,而且LA国家之间FH突变几乎没有共性。低密度脂蛋白受体突变占主导;载脂蛋白B(APOB)和前蛋白转化酶枯草溶菌素9(PCSK9)突变罕见。近50%的病例在FH基因中未发现突变。此外,还报告了一些特定国家的突变情况。关于照护模式、级联筛查、成本、治疗效果、发病率和死亡率的信息匮乏。总之,FH在LA地区大多未得到充分诊断和治疗。与原住民的基因混合产生了混血群体,这可能会影响拉丁美洲的突变研究结果。确定了缩小知识和医疗保健差距的潜在机会。

相似文献

1
The panorama of familial hypercholesterolemia in Latin America: a systematic review.
J Lipid Res. 2016 Dec;57(12):2115-2129. doi: 10.1194/jlr.R072231. Epub 2016 Oct 24.
7
Statins for children with familial hypercholesterolemia.
Cochrane Database Syst Rev. 2017 Jul 7;7(7):CD006401. doi: 10.1002/14651858.CD006401.pub4.
10
Comorbidities with Familial Hypercholesterolemia (FH): A Systematic Review.
Curr Probl Cardiol. 2023 May;48(5):101109. doi: 10.1016/j.cpcardiol.2022.101109. Epub 2022 Jan 7.

引用本文的文献

1
Interaction Between Primary Hyperlipidemias and Type 2 Diabetes: Therapeutic Implications.
Diabetes Ther. 2024 Sep;15(9):1979-2000. doi: 10.1007/s13300-024-01626-2. Epub 2024 Jul 30.
2
Comparison of Two Strategies for Hypercholesterolemia Detection through Point-of-Care Testing.
Diagnostics (Basel). 2024 Jan 8;14(2):143. doi: 10.3390/diagnostics14020143.
3
Approach to the Patient With a Suboptimal Statin Response: Causes and Algorithm for Clinical Management.
J Clin Endocrinol Metab. 2023 Aug 18;108(9):2424-2434. doi: 10.1210/clinem/dgad153.
4
Establishing the Mutational Spectrum of Hungarian Patients with Familial Hypercholesterolemia.
Genes (Basel). 2022 Jan 15;13(1):153. doi: 10.3390/genes13010153.
5
Gene Participates in the Development of Primary Dyslipidemias.
Balkan J Med Genet. 2021 Jul 27;24(1):5-14. doi: 10.2478/bjmg-2021-0009. eCollection 2021 Jun.
6
Compound Heterozygous Familial Hypercholesterolemia Caused by LDLR Variants.
Arq Bras Cardiol. 2020 Sep;115(3):587-589. doi: 10.36660/abc.20190582.
9
Use of PCSK9 Inhibitor in a Mexican Boy with Compound Heterozygous Familial Hypercholesterolemia: A Case Report.
J Endocr Soc. 2019 Nov 21;4(2):bvz018. doi: 10.1210/jendso/bvz018. eCollection 2020 Feb 1.
10
Deep-coverage whole genome sequences and blood lipids among 16,324 individuals.
Nat Commun. 2018 Aug 23;9(1):3391. doi: 10.1038/s41467-018-05747-8.

本文引用的文献

2
Progress in the care of familial hypercholesterolaemia: 2016.
Med J Aust. 2016 Sep 5;205(5):232-6. doi: 10.5694/mja16.00070.
3
Diagnostic scoring for familial hypercholesterolaemia in practice.
Curr Opin Lipidol. 2016 Aug;27(4):367-74. doi: 10.1097/MOL.0000000000000325.
4
Cardiovascular Disease Risk Associated With Familial Hypercholesterolemia: A Systematic Review of the Literature.
Clin Ther. 2016 Jul;38(7):1696-709. doi: 10.1016/j.clinthera.2016.05.006. Epub 2016 May 31.
8
Cardiovascular risk stratification in familial hypercholesterolaemia.
Heart. 2016 Jul 1;102(13):1003-8. doi: 10.1136/heartjnl-2015-308845. Epub 2016 Apr 28.
9
Identifying familial hypercholesterolemia in acute coronary syndrome.
Curr Opin Lipidol. 2016 Aug;27(4):375-81. doi: 10.1097/MOL.0000000000000311.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验